Depression is a serious mood disorder that can make people lose interest in things they once enjoyed and leave them feeling persistently sad. It's also called major depressive disorder, and it can cause various emotional and physical problems. This condition is a significant global health issue, impacting many individuals and leading to disabilities, mortality, and socioeconomic challenges.
Depression affects both men and women, making it a widespread concern worldwide. In fact, it's the most common mental disorder globally. According to a survey conducted by the National Institute of Mental Health in 2016, about 16.2 million adults in the United States experienced at least one episode of major depressive disorder. The survey revealed that the prevalence of depression was higher among adult females, with 8.5% affected, compared to males, where the rate was 4.8%.
Major depressive disorder is not only a personal struggle but also a significant public health concern. It is a leading cause of disability on a global scale and contributes significantly to the overall burden of diseases, especially in low- and middle-income countries. The Global Health Estimate Report in 2015 estimated that approximately 4.4% of the world's population experienced depression. This condition is particularly common among females aged 55 to 74.
The impact of depression extends beyond personal suffering, affecting communities and societies as a whole. The prevalence of depression seems to be on the rise each year, emphasizing the urgent need for awareness, understanding, and effective interventions. Recognizing and addressing depression is crucial not only for the well-being of individuals but also for the overall health and productivity of communities worldwide.
Efforts to combat depression require a multi-faceted approach, including increased mental health awareness, accessibility to mental health services, and destigmatization of mental health issues. Moreover, addressing socioeconomic factors that contribute to depression, such as poverty and inequality, is essential for creating a healthier and more supportive environment.
In conclusion, depression, or major depressive disorder, is a significant global health challenge affecting millions of people. Its impact goes beyond personal suffering, influencing disability rates, mortality, and socioeconomic well-being. As the prevalence of depression continues to grow, it is imperative to prioritize mental health awareness, accessibility to services, and societal changes that support mental well-being. By addressing depression comprehensively, we can work towards creating a healthier and more resilient global community.
Report Attribute/Metric | Details |
---|
Duloxetine Intermediate and Atorvastatin Intermediates Market Overview
The duloxetine intermediate and atorvastatin intermediates market is expected to reach USD 68.12 Million by 2030 at 3.90% CAGR during the forecast period 2022-2030. Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is widely approved for the treatment of stress urinary incontinence in women, major depressive disorder (MDD), and other chronic diseases. The atorvastatin intermediate is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases.
Rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, rising incidence of chronic diseases are expected to enhance the duloxetine intermediate and atorvastatin intermediates market growth. However, factors such as increasing healthcare cost and unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.
Market Dynamics
The duloxetine intermediate and atorvastatin intermediates market has been primarily driven by the rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, and growing incidence of chronic diseases. For instance, as per the survey carried out by the American Heart Association and the American College of Cardiology in 2016, around 37.5% (43.2 million) to 48.6% (56 million) of the US adults were on treatment by atorvastatin intermediate. Factors such as rising healthcare cost, unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.
Global Duloxetine Intermediate and Atorvastatin Intermediates Market Revenue, by Intermediate, 2017 & 2023 (USD Million) Â
Sources: MRFR Analysis
Segmentation
The duloxetine intermediate and atorvastatin intermediates market is segmented into an intermediate type. Based on intermediate, the market is bifurcated into duloxetine intermediates and atorvastatin intermediates. Duloxetine Intermediate segment held a duloxetine intermediate and atorvastatin intermediates market share of 32393.03 USD Million in 2017.
Key Players
The prominent players in the Duloxetine Intermediate and Atorvastatin Intermediates market are Jiangxi Aifeimu Technology Co., Ltd, Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Jigs Chemicals, Manus Aktteva, Arch Pharmalabs, Afine Chemicals Ltd, Shodhana Laboratories, Fluorochem Ltd, Chiral Bio Sciences Ltd, Tokyo Chemical Industry Co., Ltd.
Asia-Pacific Duloxetine Intermediate and Atorvastatin Intermediates Market Share, 2017 (%) Â Â Â Â
Sources: MRFR Analysis
Regional Analysis
The duloxetine intermediate and atorvastatin intermediates market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas accounts the largest market share, wherein North America is expected to dominate the market mainly due to the increasing geriatric population and the availability of advanced healthcare facilities in this region.
Europe is anticipated to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are well-established healthcare infrastructure and the increase in adoption of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disease and major mental disorders.
Asia-Pacific is estimated to be the fastest-growing region in the duloxetine intermediate and atorvastatin intermediates market. This can be attributed to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. Japan held a market share of 18.5% in 2017.
Also, the duloxetine intermediate and atorvastatin intermediates market in the Middle East and Africa region is projected to account for the least share during the review period. The Middle East is expected to influence the market owing to the increasing use of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disorders in Saudi Arabia, Kuwait, and the UAE.
Market Segmentation
Duloxetine Intermediate and Atorvastatin Intermediates Market, by Intermediate Type
Duloxetine Intermediate and Atorvastatin Intermediates Market, by Region
Available Additional Customizations
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)